Printer Friendly

MDxHealth announces positive results on MGMT test.

(SeeNews) - Jul 11, 2011 - Belgian-based biotechnology company MDxHealth (EBR:ONCOB), former Oncomethylome Sciences, said today a study on its MGMT test for brain cancer has proved its efficacy.

The MGMT test has shown to be the only prognostic factor for overall survival in newly diagnosed glioblastoma multiforme (GBM) patients over the age of 70, the company added. A prognostic factor is a biological marker that helps determine the course and outcome of a disease. The results were published in the Journal of Clinical Oncology.

"This study confirms the results of a steadily increasing number of clinical trial reports that support the importance of MDxHealth's PredictMDx for Brain test in clinical decision making", CEO Jan Groen said.
COPYRIGHT 2011 AII Data Processing Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ADP News Belgium
Date:Jul 11, 2011
Previous Article:Baronie to buy Barry Callebaut's European consumer arm.
Next Article:Omega Pharma mulls over possible bourse exit.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters